This week's View summarizes two recent publications, one a trial showing that a 5-day course of remdesivir was superior to standard therapy at improving clinical status among patients with moderate coronavirus disease 2019 infection, and the other a prespecified secondary analysis within the PARAGON-HF trial looking at the impact of angiotensin-neprilysin inhibition on renal events among patients with heart failure with preserved ejection fraction.